Could a common arthritis drug calm heart inflammation?
NCT ID NCT06868381
First seen Feb 19, 2026 · Last updated Jun 20, 2026 · Updated 17 times
Summary
This early trial tests whether baricitinib, an immune-calming drug already used for arthritis, can reduce heart inflammation in people with cardiac sarcoidosis. Ten adults will take the drug for 16 weeks alongside their usual steroid-sparing medication. Researchers will use PET scans to see if the inflammation in the heart gets better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304-2210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
baricitinib (a drug that calms the immune system)
What this could lead to
If it works, this could point toward a new treatment option for cardiac sarcoidosis, potentially reducing heart inflammation without high-dose steroids.
What could go wrong
This is a very small, early-phase trial with only 10 people, so results may not apply to everyone. Baricitinib can also increase infection risk and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.